1. P. Hartsock and S.G. Genser, eds., Longitudinal Studies of HIV Infection in Intravenous Drug Users.NIDA Research Monograph 109. GPO, Washington, D.C. (1991).
2. D. C. Des Jarlais, S.R. Friedman, and R.L. Stonebumer, HIV infection and intravenous drug use:Critical issues in transmission dynamics, infection outcomes and prevention, Rev Infect Dis. 10:151(1988).
3. E. E. Schoenbaum, D Hartel, P.A. Selwyn, R.S. Klein, K. Davenny, M. Rogers, C. Feiner, and G.Friedland. Risk factors for human immunodeficiency virus infection in intravenous drug users, New Engl. J Med. 321:874 (1989).
4. D. C. Des Jarlais, S.R. Friedman, M. Marmor, H. Cohen, D. Mildvan, S. Yancovitz, U. Mathur, W. El-Sadr, T.J Spira, J. Garber, S.T. Beatrice, A.S. Abdul-Quader, and J.L. Sotheran, Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users, AIDS 1:105 (1987).
5. R. L. Stoneburner, D.C. Des Jarlais, D. Benezra, L. GoreLlcin, J.L. Sotheran, S.R. Friedman, S. Schultz,M. Marmor, D. Mildvan, and R. Maslansky, A larger spectrum of severe HIV-1-related disease in intravenous drug users in New York City, Science242:916 (1988).